Meeting
2024 ASCO Annual Meeting
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
Presenter
Vanesa Gregorc, MD
Candiolo Cancer Institute, FPO-IRCCS
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Targeting KRAS in Non–Small Cell Lung Cancer
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05756153
Citation
J Clin Oncol 42, 2024 (suppl 17; abstr LBA8511)
DOI
10.1200/JCO.2024.42.17_suppl.LBA8511
Abstract #
LBA8511
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
Speaker: Jun Zhao, PhD
Videos & Slides
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.
Speaker: Sawsan Rashdan, MD
Speaker: Panel Discussion
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase II trial to assess the efficacy and safety of bevacizumab plus mFOLFOX6 as induction chemotherapy toward R0 surgical resection in advanced colorectal liver metastases with mutant-type KRAS: NEXTO-mt trial.
Speaker: Genki Watanabe